Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GD2-CART01 in Pediatric High Risk/Relapsed Neuroblastoma and GD2-positive Solid Tumors
NCT03373097Phase 2Active, not recruiting
- Start
- Jan 2018
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of GD2-CART01 in neuroblastoma, osteosarcoma (OS), Ewing sarcoma, sarcoma. Started Jan 2018; status: active, not recruiting.
02
Drugs
GD2-CART01
03
Conditions
neuroblastomaosteosarcoma (OS)Ewing sarcomasarcoma
Beyond the preview
Go deeper on NCT03373097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03373097.